Analysts Set Roivant Sciences Ltd. (NASDAQ:ROIV) Price Target at $18.08

Roivant Sciences Ltd. (NASDAQ:ROIV) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $18.08.

A number of research firms have weighed in on ROIV. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $10.79 on Wednesday. Roivant Sciences has a 52-week low of $9.93 and a 52-week high of $13.06. The firm has a 50 day moving average price of $10.78 and a two-hundred day moving average price of $11.47. The stock has a market cap of $7.70 billion, a P/E ratio of -71.93 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Analysts predict that Roivant Sciences will post -0.92 earnings per share for the current fiscal year.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was bought at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the purchase, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. The trade was a 21.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CIO Mayukh Sukhatme sold 689,495 shares of the stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $12.01, for a total transaction of $8,280,834.95. Following the sale, the executive now directly owns 18,836,547 shares in the company, valued at $226,226,929.47. This trade represents a 3.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,875,586 shares of company stock worth $21,491,661 in the last three months. 7.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Roivant Sciences

Institutional investors have recently made changes to their positions in the business. FMR LLC raised its stake in Roivant Sciences by 0.3% during the 4th quarter. FMR LLC now owns 49,301,583 shares of the company’s stock worth $583,238,000 after acquiring an additional 156,527 shares during the period. Vanguard Group Inc. grew its holdings in shares of Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after purchasing an additional 2,404,232 shares in the last quarter. State Street Corp grew its holdings in shares of Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after purchasing an additional 1,118,561 shares in the last quarter. Patient Square Capital LP grew its holdings in shares of Roivant Sciences by 2.1% in the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company’s stock valued at $147,638,000 after purchasing an additional 251,535 shares in the last quarter. Finally, Two Seas Capital LP boosted its stake in Roivant Sciences by 4.6% during the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company’s stock worth $120,285,000 after buying an additional 442,914 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.